Evidence map›Paper›PMID 39544927›Full record

ArticleFrontiers in immunology2024

Mariona Cortacans, Marta Arch, Esther Fuentes, Pere-Joan Cardona

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Frontiers in cellular and infection microbiology · 2026
    Article
  3. The "yeast-drop" treatment protocol in theFrontiers in tuberculosis · 2026
    Article
  4. Review
  5. Frontiers in tuberculosis · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mariona CortacansServei de Microbiologia, Laboratori Clínic de la Metropolitana Nord (LCMN), Hospital Universitari Germans Trias i Pujol (HUGTiP), Badalona, Spain.
Marta ArchServei de Microbiologia, Laboratori Clínic de la Metropolitana Nord (LCMN), Hospital Universitari Germans Trias i Pujol (HUGTiP), Badalona, Spain.
Esther FuentesServei de Microbiologia, Laboratori Clínic de la Metropolitana Nord (LCMN), Hospital Universitari Germans Trias i Pujol (HUGTiP), Badalona, Spain.
Pere-Joan CardonaServei de Microbiologia, Laboratori Clínic de la Metropolitana Nord (LCMN), Hospital Universitari Germans Trias i Pujol (HUGTiP), Badalona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intorduction: Pathogens drive the evolution of host defence strategies, with both innate and adaptive immune systems playing key roles. Priming enhances the innate immune system's readiness by functionally reprogramming immune cells after initial exposure to stimuli, like β-glucans. In this sense, Objectives: In this study we aimed to set light on the immune priming effect of oral treatment with heat-killed Methods: A clinical and a control ATCC 90028 Results: Both treatments showed a significant capacity to enhance the expression of antimicrobial peptides, in particular Diptericin, and Drosomycin in males. This response had a marked sexual dimorphism due to the difference in Upd3, Nox, and Duox expression. Surprisingly, even when priming was able to avoid the growth of both Conclusion: Data herein suggests the presence of a strain-specific component in

Indexed as

Candida albicansCandidiasisDisease Models, AnimalDrosophila melanogasterDrosophila ProteinsImmunity, InnateAnimalsAntimicrobial PeptidesFemaleHost-Pathogen InteractionsMaleVirulenceVirulence FactorsAntimicrobial PeptidesDptA protein, DrosophilaDrosophila ProteinsDRS protein, DrosophilaVirulence FactorsDrosophila melanogasterenvironmental mycobacteriainfectioninnate immunitypathogen loadprimingsexual dimorphismβ-glucan

Identifiers

PMID39544927
PMCPMC11560421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.